EHA Library - The official digital education library of European Hematology Association (EHA)

CIRCULATING ENDOTHELIAL PROGENITORS CELLS AND METABOLIC FACTORS IN CHILDHOOD CANCER SURVIVORS
Author(s):
Emmanouil Athanasopoulos
,
Emmanouil Athanasopoulos
Affiliations:
Pediatric Hematology - Oncology,University Hospital of Heraklion, University of Crete,Heraklion,Greece
Georgia Martimianaki
,
Georgia Martimianaki
Affiliations:
Pediatric Hematology - Oncology,University Hospital of Heraklion, University of Crete,Heraklion,Greece
Helen Kampouraki
,
Helen Kampouraki
Affiliations:
Pediatric Hematology - Oncology,University Hospital of Heraklion, University of Crete,Heraklion,Greece
Maria Stratigaki
,
Maria Stratigaki
Affiliations:
Pediatric Hematology - Oncology,University Hospital of Heraklion, University of Crete,Heraklion,Greece
Erasmia Athina Markaki
,
Erasmia Athina Markaki
Affiliations:
Pediatric Hematology - Oncology,University Hospital of Heraklion, University of Crete,Heraklion,Greece
Nikolaos Katzilakis
,
Nikolaos Katzilakis
Affiliations:
Pediatric Hematology - Oncology,University Hospital of Heraklion, University of Crete,Heraklion,Greece
Eftichia Stiakaki
Eftichia Stiakaki
Affiliations:
Pediatric Hematology - Oncology,University Hospital of Heraklion, University of Crete,Heraklion,Greece
(Abstract release date: 05/18/17) EHA Library. Stiakaki E. 05/18/17; 182568; PB1854
Prof. Dr. Eftichia Stiakaki
Prof. Dr. Eftichia Stiakaki
Contributions
PDF Abstract
Abstract

Abstract: PB1854

Type: Publication Only

Background

Circulating Endothelial Progenitor Cells (CEPCs) play a significant role in the maintenance of vascular integrity,balancing the anti-coagulation mechanisms and modulating the immune system by regulating the leukocyte trafficking, as well as controlling the vascular tone. Additionally, it is well-established, that patients who underwent chemotherapy have increased incidence of hypertension and obesity. Nevertheless, numerous studies have shown a negative correlation between CEPCs and obesity, underlining poor vascular repair.

Aims

The study of CEPCs in children who received chemotherapy for Acute Lymphoblastic Leukemia (ALL) and solid tumors (ST) and the investigation of their levels in correlation with patients Body Mass Index (BMI) and blood pressure (BP) regarding the time following treatment.

Methods
Peripheral blood from children with ALL (n=77), ST (n=81) and children without malignancies as control group ( n=71) were studied. Four colour flow cytometry was performed to determine the subpopulations CD34+CD45negdimCD133+, CD34+CD45negdimVEGFR2+ and CD34+CD45negdimCD133+VEGFR2+ of CEPCs. The BMI of the patients was calculated and the BMI percentile was established specific by the age and gender. Normal weight defined with BMI percentile over 5th and bellow 85th percentile, and overweight/obesity over 85th percentile. The systolic blood pressure (BP) was measured and the percentile was calculated specified by the age, gender and height. Normal BP was defined BP over 5th and bellow 90th percentile and hypertension with a BP over 90th percentile. The post treatment period of time was divided in three groups under or equal of 1 year, 1 to 3 years, and equal and over 3 years. The statistical analysis was conducted using t-test (Holm-Sidak) and 2way ANOVA (Tukey's multiple comparisons test).

Results

The mean values of CEPCs subpopulation CD34+CD45negdimVEGFR2+ estimated in ALL, ST and Controls were 0.00360 (SE=0.00072),0.00613 (SE=0.00146) and 0.002953 (SE=0.0004) respectively. The mean percentage of CD34+CD45negdimCD133+VEGFR2+ in ALL, ST and Controls was 0.00331 (SE=0.00072), 0.00499 (SE=0.00113) and 0.002663 (SE=0.00037). The correlation of CEPCs showed statistical significant difference of CD34+CD45negdimVEGFR2+ between the ST and controls (Mean Diff 0.003174, 95CI of diff 7.716e-005 to 0.006272). In ALL the levels of CD34+CD45negdimVEGFR2+ the 1st year after treatment completion were 0.00458(SE=0.0026), during 1-3years 0.0031(SE=0.00066) and >3 years 0.003423(SE 0.00081). The levels of CD34+CD45negdimCD133+VEGFR2+ during the 1st year after chemotherapy have a mean value 0.0045(SE=0.0026), 1-3 years 0.0027(SE=0.00063) and >3years 0.0031(SE=0.00081). In the ST group the mean value of CD34+CD45negdimVEGFR2+ the 1st year after treatment was 0.0114 (SE=0.0048),1-3years 0.0047(SE=0.0013) and >3 years 0.0036(SE=0.0008). Whereas the percentage of CD34+CD45negdimCD133+VEGFR2+ the 1st year after chemotherapy was 0.0092 (SE=0.0037),1-3 years 0.0034(SE=0.00097)and>3 years 0.00336(SE=0.00085).Statistical significant results were calculated for the levels of CD34+CD45negdimVEGFR2+ in ST group between the groups <1 year and over years’ post treatment(Mean Diff 0.007747, 95 CI of diff 0.0002441 to 0.01525). The study of body weight in ALL and ST groups in relation with CEPCs showed no statistical significant difference, although a negative trend between obesity and CEPCs was found in the ALL group and a positive one in the ST group. The same trend also appeared in BP between ALL and ST regarding the CEPCs, with hypertensive patients in ALL group having higher levels of CEPCs than the ST hypertensive individuals.

Conclusion
The higher levels of CEPCs were estimated in ALL and ST just after treatment completion with a gradual decrease as time passes. The highest percentages of CEPCs were evaluated in ALL patients with normal weight and blood pressure in contrast with the solid tumor group. Further invstigation is necessary to highlight the importance of these data.

Session topic: 23. Hematopoiesis, stem cells and microenvironment

Keyword(s): Metabolic syndrome, Endothelial progenitor cell, Childhood, Cancer

Abstract: PB1854

Type: Publication Only

Background

Circulating Endothelial Progenitor Cells (CEPCs) play a significant role in the maintenance of vascular integrity,balancing the anti-coagulation mechanisms and modulating the immune system by regulating the leukocyte trafficking, as well as controlling the vascular tone. Additionally, it is well-established, that patients who underwent chemotherapy have increased incidence of hypertension and obesity. Nevertheless, numerous studies have shown a negative correlation between CEPCs and obesity, underlining poor vascular repair.

Aims

The study of CEPCs in children who received chemotherapy for Acute Lymphoblastic Leukemia (ALL) and solid tumors (ST) and the investigation of their levels in correlation with patients Body Mass Index (BMI) and blood pressure (BP) regarding the time following treatment.

Methods
Peripheral blood from children with ALL (n=77), ST (n=81) and children without malignancies as control group ( n=71) were studied. Four colour flow cytometry was performed to determine the subpopulations CD34+CD45negdimCD133+, CD34+CD45negdimVEGFR2+ and CD34+CD45negdimCD133+VEGFR2+ of CEPCs. The BMI of the patients was calculated and the BMI percentile was established specific by the age and gender. Normal weight defined with BMI percentile over 5th and bellow 85th percentile, and overweight/obesity over 85th percentile. The systolic blood pressure (BP) was measured and the percentile was calculated specified by the age, gender and height. Normal BP was defined BP over 5th and bellow 90th percentile and hypertension with a BP over 90th percentile. The post treatment period of time was divided in three groups under or equal of 1 year, 1 to 3 years, and equal and over 3 years. The statistical analysis was conducted using t-test (Holm-Sidak) and 2way ANOVA (Tukey's multiple comparisons test).

Results

The mean values of CEPCs subpopulation CD34+CD45negdimVEGFR2+ estimated in ALL, ST and Controls were 0.00360 (SE=0.00072),0.00613 (SE=0.00146) and 0.002953 (SE=0.0004) respectively. The mean percentage of CD34+CD45negdimCD133+VEGFR2+ in ALL, ST and Controls was 0.00331 (SE=0.00072), 0.00499 (SE=0.00113) and 0.002663 (SE=0.00037). The correlation of CEPCs showed statistical significant difference of CD34+CD45negdimVEGFR2+ between the ST and controls (Mean Diff 0.003174, 95CI of diff 7.716e-005 to 0.006272). In ALL the levels of CD34+CD45negdimVEGFR2+ the 1st year after treatment completion were 0.00458(SE=0.0026), during 1-3years 0.0031(SE=0.00066) and >3 years 0.003423(SE 0.00081). The levels of CD34+CD45negdimCD133+VEGFR2+ during the 1st year after chemotherapy have a mean value 0.0045(SE=0.0026), 1-3 years 0.0027(SE=0.00063) and >3years 0.0031(SE=0.00081). In the ST group the mean value of CD34+CD45negdimVEGFR2+ the 1st year after treatment was 0.0114 (SE=0.0048),1-3years 0.0047(SE=0.0013) and >3 years 0.0036(SE=0.0008). Whereas the percentage of CD34+CD45negdimCD133+VEGFR2+ the 1st year after chemotherapy was 0.0092 (SE=0.0037),1-3 years 0.0034(SE=0.00097)and>3 years 0.00336(SE=0.00085).Statistical significant results were calculated for the levels of CD34+CD45negdimVEGFR2+ in ST group between the groups <1 year and over years’ post treatment(Mean Diff 0.007747, 95 CI of diff 0.0002441 to 0.01525). The study of body weight in ALL and ST groups in relation with CEPCs showed no statistical significant difference, although a negative trend between obesity and CEPCs was found in the ALL group and a positive one in the ST group. The same trend also appeared in BP between ALL and ST regarding the CEPCs, with hypertensive patients in ALL group having higher levels of CEPCs than the ST hypertensive individuals.

Conclusion
The higher levels of CEPCs were estimated in ALL and ST just after treatment completion with a gradual decrease as time passes. The highest percentages of CEPCs were evaluated in ALL patients with normal weight and blood pressure in contrast with the solid tumor group. Further invstigation is necessary to highlight the importance of these data.

Session topic: 23. Hematopoiesis, stem cells and microenvironment

Keyword(s): Metabolic syndrome, Endothelial progenitor cell, Childhood, Cancer

Premium Sponsors

What's new at EHA

Browse the open-source material from EHA past Congresses and meetings.

References

EHA Terms & Conditions
2025 ©
European Hematology Association
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies